アブストラクト
| Title | SGLT2阻害薬 |
|---|---|
| Subtitle | 特集 Fantastic Four時代の心不全の治療戦略 心不全へのFantastic Fourの使い方 |
| Authors | 堀内優 |
| Authors (kana) | |
| Organization | 三井記念病院循環器内科 |
| Journal | 月刊薬事 |
| Volume | 65 |
| Number | 9 |
| Page | 1735-1738 |
| Year/Month | 2023 / 7 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Key Points] ●SGLT2は近位尿細管におけるグルコースの再吸収を司っている. ●SGLT2阻害薬は尿中へのグルコースとナトリウムの排泄を促進する. ●心不全患者においてはうっ血の改善, 腎保護作用, 貧血改善, 心筋エネルギー代謝の改善などの多面的な影響をもつ. ●糖尿病の有無や左室駆出率にかかわらず, 心不全患者の心血管死亡・心不全再入院のアウトカムを改善させる. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Zelniker TA, et al: Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review. J Am Coll Cardiol, 72:1845-1855, 2018
- 2) Turnbull FM, et al: Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia, 52:2288-2298, 2009
- 3) Zinman B, et al; EMPA-REG OUTCOME Investigators:Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med, 373:2117-2128, 2015
- 4) Neal B, et al; CANVAS Program Collaborative Group: Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med, 377:644-657, 2017
- 5) Wiviott SD, et al; DECLARE? TIMI 58 Investigators: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 380:347-357, 2019
残りの9件を表示する
- 6) Verma S, et al: SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia, 61:2108-2117, 2018
- 7) Sano M, et al: Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects. Circulation, 139:1985-1987, 2019
- 8) Packer M, et al; EMPEROR-Reduced Trial Investigators: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med, 383:1413-1424, 2020
- 9) McMurray JJV, et al; DAPA-HF Trial Committees and Investigators: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med, 381:1995-2008, 2019
- 10) Solomon SD, et al; DELIVER Trial Committees and Investigators: Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med, 387:1089-1098, 2022
- 11) Anker SD, et al; EMPEROR-Preserved Trial Investigators: Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med, 385:1451-1461, 2021
- 12) Vaduganathan M, et al: SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet, 400:757-767, 2022
- 13) Martinez FA, et al: Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Circulation, 141:100-111, 2020
- 14) Adamson C, et al: Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Eur J Heart Fail, 23:1662-1672, 2021
